EL7.AI
StocksMedium•30 March 2026•
1 min read

AnaptysBio to Spin Off Biopharma Unit and Launches $100M Buyback Program

Key Facts

1AnaptysBio will spin off its biopharma operations into a new entity called First Tracks Biotherapeutics (TRAX) by April 20, 2026.
2CEO Daniel Faga sold 2,570 shares at approximately $57.91 each, but still retains 510,564 shares.
3The company announced a $100 million stock repurchase plan, and the new entity (TRAX) will launch with a $180 million cash balance.

AnaptysBio (ANAB) has announced a strategic restructuring plan to spin off its biopharma operations into a new entity, First Tracks Biotherapeutics (TRAX). The spin-off is expected to be completed by April 20, 2026, with the new company launching with a robust cash balance of $180 million. Alongside the restructuring, AnaptysBio unveiled a $100 million share repurchase program aimed at enhancing shareholder value. In recent insider activity, CEO Daniel Faga sold 2,570 shares at an average price of $57.91, though he maintains a significant stake of over 510,000 shares. The move is designed to sharpen the company's focus on next-generation antibody therapeutics while optimizing capital allocation. Market analysts view the combination of the spin-off and buyback as a strategic effort to unlock value, despite the minor insider selling.